Mednet Logo
HomeMedical OncologyQuestion

Is there any benefit to changing a monoclonal EGFR inhibitor therapy when one had to be stopped for cutaneous toxicity?

2
1 Answers
Mednet Member
Mednet Member
Medical Oncology · Rutgers Cancer Institute of New Jersey

The two anti-EGFR monoclonals both have high rates of cutaneous toxicity. It isn't clear that one is better than the other, so switching Is not a good option. It is better to reduce the dose and treat through with doxycycline and steroids. Generally the rash will improve within 4-6 weeks. In the cas...

Register or Sign In to see full answer